Roivant Sciences Ltd.
ROIVNasdaqCIK 1635088HealthcareFiscal year ends Mar 31
All transactions: 4
Non-derivative transactions reported on Forms 4, newest first. Purchases and sales (codes P and S) are open-market trades; the other codes are grants, exercises, withholding and gifts. The reported price is as stated on the form, not a market price.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-10-23 | Momtazee James CDirector | Tax withholding | 77 | $36.49 | $2.8k | Form 4 |
| 2026-10-23 | Momtazee James CDirector | Grant or award | 383 | $0.00 | $0 | Form 4 |
| 2026-10-20 | Venker EricPresident & Immunovant CEO, Officer | Sale | 14,144 | $35.42 | $501.0k | Form 4 |
| 2026-10-20 | Venker EricPresident & Immunovant CEO, Officer | Sale | 185,856 | $35.09 | $6.5m | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Nov 3, 2026, 20:10 ET. Listed shows no prices and gives no investment advice.